| Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases Y Tang, MT Nakada, P Kesavan, F McCabe, H Millar, P Rafferty, ... Cancer research 65 (8), 3193-3199, 2005 | 499 | 2005 |
| Regulation of vascular endothelial growth factor expression by EMMPRIN via the PI3K-Akt signaling pathway Y Tang, MT Nakada, P Rafferty, J Laraio, FL McCabe, H Millar, ... Molecular cancer research 4 (6), 371-377, 2006 | 173 | 2006 |
| Amivantamab (JNJ-61186372), an Fc enhanced EGFR/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte/macrophage trogocytosis S Vijayaraghavan, L Lipfert, K Chevalier, BS Bushey, B Henley, R Lenhart, ... Molecular cancer therapeutics 19 (10), 2044-2056, 2020 | 134 | 2020 |
| Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies EC Pietsch, J Dong, R Cardoso, X Zhang, D Chin, R Hawkins, T Dinh, ... Blood cancer journal 7 (2), e536-e536, 2017 | 111 | 2017 |
| CNTO 859, a humanized anti‐tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models CV Ngo, K Picha, F McCabe, H Millar, R Tawadros, SH Tam, MT Nakada, ... International journal of cancer 120 (6), 1261-1267, 2007 | 110 | 2007 |
| CNTO 95, a fully human anti αv integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells Q Chen, CD Manning, H Millar, FL McCabe, C Ferrante, C Sharp, ... Clinical & experimental metastasis 25, 139-148, 2008 | 102 | 2008 |
| Discovery and pharmacological characterization of JNJ-64619178, a novel small-molecule inhibitor of PRMT5 with potent antitumor activity D Brehmer, L Beke, T Wu, HJ Millar, C Moy, W Sun, G Mannens, V Pande, ... Molecular cancer therapeutics 20 (12), 2317-2328, 2021 | 63 | 2021 |
| αv integrin-targeted immunoconjugates regress established human tumors in xenograft models Q Chen, HJ Millar, FL McCabe, CD Manning, R Steeves, K Lai, B Kellogg, ... Clinical cancer research 13 (12), 3689-3695, 2007 | 42 | 2007 |
| Development of a CD123xCD3 bispecific antibody (JNJ-63709178) for the treatment of acute myeloid leukemia (AML) F Gaudet, JF Nemeth, R McDaid, Y Li, B Harman, H Millar, A Teplyakov, ... Blood 128 (22), 2824, 2016 | 35 | 2016 |
| Circulating Human Interleukin-8 as an Indicator of Cancer Progression in a Nude Rat Orthotopic Human Non–Small Cell Lung Carcinoma Model HJ Millar, JA Nemeth, FL McCabe, B Pikounis, E Wickstrom Cancer Epidemiology Biomarkers & Prevention 17 (8), 2180-2187, 2008 | 35 | 2008 |
| JNJ-64619178, a selective and pseudo-irreversible PRMT5 inhibitor with potent in vitro and in vivo activity, demonstrated in several lung cancer models T Wu, H Millar, D Gaffney, L Beke, G Mannens, P Vinken, I Sommers, ... Cancer Research 78 (13_Supplement), 4859-4859, 2018 | 27 | 2018 |
| Abstract DDT02-04: A novel PRMT5 inhibitor with potent in vitro and in vivo activity in preclinical lung cancer models D Brehmer, T Wu, G Mannens, L Beke, P Vinken, D Gaffney, W Sun, ... Cancer research 77 (13_Supplement), DDT02-04-DDT02-04, 2017 | 27 | 2017 |
| In vivo efficacy and pharmacodynamic modulation of JNJ-64619178, a selective PRMT5 inhibitor, in human lung and hematologic preclinical models HJ Millar, D Brehmer, T Verhulst, N Haddish-Berhane, T Greway, ... Cancer Research 79 (13_Supplement), 950-950, 2019 | 12 | 2019 |
| CNTO 859, a Humanized Anti-Tissue Factor Monoclonal Antibody, Inhibits Lung Metastasis and Tumor Growth in MDA-MB-231 Breast Cancer Xenograft Models GMA C. Ngo, R. Tawadros, F. McCabe, H. Millar, M. Nakada Pathophysiology of Haemostasis and Thrombosis 33 (suppl 1), 71, 2003 | 8* | 2003 |
| Combination antibody therapy targeting both xenograft-and host-derived tissue factor leads to potent tumor inhibition CV Ngo, CA Manning, F McCabe, H Millar, MT Nakada, GM Anderson Cancer Research 65 (9_Supplement), 129-129, 2005 | 7 | 2005 |
| 529 POSTER Anti-tumor efficacy of the integrin-targeted immunoconjugate IMGN388 in preclinical models CA Vater, C Manning, H Millar, F McCabe, Q Chen, GM Anderson, ... Ejc Supplements 12 (6), 167-168, 2008 | 6 | 2008 |
| Neutralization of CCL2 inhibits tumor angiogenesis and pancreatic tumor growth L Snyder, P Kesavan, E Kaiser, K Rudnick, F McCabe, H Millar, M Nakada, ... Molecular Cancer Therapeutics 6 (11_Supplement), A69-A69, 2007 | 6 | 2007 |
| Neutralizing CCL2 Inhibits Breast Tumor Growth Via Impact on the Tumor/Stroma Microenvironment. L Campion, F Shi, E Kaiser, L Johns, D Egenolf, C Ferrante, F McCabe, ... Cancer Research 69 (24_Supplement), 6095-6095, 2009 | 4 | 2009 |
| Anti-CCL-2/MCP-1 (monocyte chemoattractant protein-1) monoclonal antibodies effectively inhibit tumor angiogenesis and growth of human breast carcinoma P Kesavan, F McCabe, H Millar, N Stowell, D Griswold, A Das, M Nakada, ... Cancer Res 65, 254, 2005 | 3 | 2005 |
| Inhibition of NF-kB inducing kinase (NIK) selectively abrogates NIK and TRAF3 mutant multiple myeloma tumor growth M Versele, L Janssen, T Geerts, W Floren, B Janssens, H Millar, E Jacoby, ... Cancer Research 77 (13_Supplement), 4199-4199, 2017 | 2 | 2017 |
Susan TamVP, Discovery ResearchDirección de correo verificada de tavotek.com
